ONO-7475 Phase I Study (ONO-7475-02)

Open-label, uncontrolled, dose-escalation study of ONO-7475 given as monotherapy and combinations with ONO-4538 in patients with advanced or metastatic solid tumors (ONO-7475-02)

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080224028

Enrollment

Registered

2018-08-29

Start date

2018-11-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Solid tumors

Interventions

investigational material(s) Generic name etc : ONO-7475 INN of investigational material : ONO-7475 Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with histologically or cytologically confirmed advanced or metastatic solid tumors 2. ECOG Performance Status 0-1 3. Patients with life expectancy of at least 3 months

Exclusion criteria

Exclusion criteria: 1. Patients with history of serious allergy 2. Patients with multiple cancers

Design outcomes

Primary

Measure	Time frame
safety Tolerability, Safety	—

Secondary

Measure	Time frame
pharmacokinetics Pharmacokinetics	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026